Abivax: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Abivax}} | ||
[[File:Abivax_Logo_2023.png|thumb|right|Abivax logo]] | |||
'''Abivax''' is a | '''Abivax''' is a clinical-stage biotechnology company focused on developing therapies that modulate the body's natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. The company is headquartered in Paris, France, and is known for its innovative approach to drug development. | ||
==History== | ==History== | ||
Abivax was founded in 2013 with the aim of leveraging the immune system to | Abivax was founded in 2013 with the aim of leveraging the immune system to address unmet medical needs. Since its inception, the company has been involved in the development of several promising drug candidates. | ||
==Research and Development== | ==Research and Development== | ||
Abivax's research and development efforts are | Abivax's research and development efforts are centered around its proprietary technology platforms, which include small molecules and biologics designed to modulate the immune response. | ||
===ABX464=== | ===ABX464=== | ||
One of Abivax's | One of Abivax's lead drug candidates is '''ABX464''', a small molecule with anti-inflammatory properties. It is being investigated for the treatment of [[ulcerative colitis]], [[Crohn's disease]], and other inflammatory conditions. ABX464 works by enhancing the expression of a specific microRNA, miR-124, which plays a role in regulating inflammation. | ||
===ABX196=== | ===ABX196=== | ||
Another key | Another key candidate is '''ABX196''', an immune enhancer being developed for the treatment of [[hepatocellular carcinoma]] and other cancers. ABX196 is a synthetic glycolipid agonist of iNKT cells, which are a type of immune cell involved in tumor surveillance. | ||
== | ==Clinical Trials== | ||
Abivax | Abivax is actively conducting clinical trials to evaluate the safety and efficacy of its drug candidates. The company has reported promising results from its Phase 2 trials of ABX464 in patients with ulcerative colitis, demonstrating significant clinical remission rates. | ||
==Collaborations== | ==Partnerships and Collaborations== | ||
Abivax | Abivax collaborates with various academic institutions and industry partners to advance its research and development programs. These collaborations are crucial for accessing new technologies and expanding the potential applications of its drug candidates. | ||
== | ==Future Directions== | ||
The company | The company aims to continue advancing its pipeline through clinical development and regulatory approval processes. Abivax is committed to addressing significant unmet medical needs and improving patient outcomes through innovative therapies. | ||
== | ==Related pages== | ||
* [[Biotechnology]] | * [[Biotechnology]] | ||
* [[Immunotherapy]] | * [[Immunotherapy]] | ||
* [[ | * [[Inflammatory diseases]] | ||
* [[ | * [[Cancer treatment]] | ||
[[Category:Biotechnology companies | [[Category:Biotechnology companies]] | ||
[[Category:Pharmaceutical companies of France]] | [[Category:Pharmaceutical companies of France]] | ||
[[Category:Companies established in 2013]] | [[Category:Companies established in 2013]] | ||
Latest revision as of 03:31, 13 February 2025
Abivax is a clinical-stage biotechnology company focused on developing therapies that modulate the body's natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. The company is headquartered in Paris, France, and is known for its innovative approach to drug development.
History[edit]
Abivax was founded in 2013 with the aim of leveraging the immune system to address unmet medical needs. Since its inception, the company has been involved in the development of several promising drug candidates.
Research and Development[edit]
Abivax's research and development efforts are centered around its proprietary technology platforms, which include small molecules and biologics designed to modulate the immune response.
ABX464[edit]
One of Abivax's lead drug candidates is ABX464, a small molecule with anti-inflammatory properties. It is being investigated for the treatment of ulcerative colitis, Crohn's disease, and other inflammatory conditions. ABX464 works by enhancing the expression of a specific microRNA, miR-124, which plays a role in regulating inflammation.
ABX196[edit]
Another key candidate is ABX196, an immune enhancer being developed for the treatment of hepatocellular carcinoma and other cancers. ABX196 is a synthetic glycolipid agonist of iNKT cells, which are a type of immune cell involved in tumor surveillance.
Clinical Trials[edit]
Abivax is actively conducting clinical trials to evaluate the safety and efficacy of its drug candidates. The company has reported promising results from its Phase 2 trials of ABX464 in patients with ulcerative colitis, demonstrating significant clinical remission rates.
Partnerships and Collaborations[edit]
Abivax collaborates with various academic institutions and industry partners to advance its research and development programs. These collaborations are crucial for accessing new technologies and expanding the potential applications of its drug candidates.
Future Directions[edit]
The company aims to continue advancing its pipeline through clinical development and regulatory approval processes. Abivax is committed to addressing significant unmet medical needs and improving patient outcomes through innovative therapies.
